Breaking News

Initium Therapeutics Launches Antibody Development Platform

Expands its antibody drug pipeline using GenScript Bio’s Berkeley Lights Beacon platform.

By: Contract Pharma

Contract Pharma Staff

On December 7, 2020, GenScript ProBio and Initium Therapeutics announced that Initium Therapeutics has launched a single B-cell based antibody development platform through collaboration with GenScript ProBio.   Initium Therapeutics is a US biotechnology company, a spin-off from South Korean biotech company Tiumbio, seeking antibody-based therapeutics for patients who are suffering from unaddressed incurable and rare diseases.   Goals of the Partnership   The strategic collaboration between the t...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters